Jälki-ilmoitus EU-hankinta

Meningococcal group A, C, W-135 and Y conjugate vaccine (Men ACWY) 2026-2027 (2028, 2029)

Ministry of Social Affairs and Health · Uusimaa

Perustiedot

Hankkija
Ministry of Social Affairs and Health, Y-tunnus 0244685-8
Toteutuspaikka
Uusimaa (FI1B1)
Hankintalaji
Tavarahankinta
Menettely
Avoin menettely, EU-hankinta
Ilmoituksen tyyppi
Jälki-ilmoitus
Sopimusten kokonaisarvo
2 485 056 € (alv 0 %)
Pääasiallinen CPV
33651600 Rokotteet
Lisäkoodit: 33600000, 33650000
Sopimuskausi
24 kuukautta
Julkaistu
26.9.2025

Hankinnan tulos

Voittaja Sopimusarvo Tarjouksia Päätös
GlaxoSmithKline Oy, Y-tunnus 0108378-4 2 485 056 € ei ilmoitettu

Voittajista näytetään nimi ja Y-tunnus. ”Ei ilmoitettu” tarkoittaa, ettei ilmoituksessa ole tätä tietoa erälle tai sopimukselle.

Ilmoituksen teksti

Alkuperäinen teksti Hilmasta, muuttamattomana
The Ministry of Social Affairs and Health (later referred to as ”STM”) and the Finnish Institute for Health and Welfare (later referred to as "THL" or “Customer” ) request your tender for Meningococcal group A, C, W-135 and Y conjugate vaccine, required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The contract period is two years 2026 - 2027. The procurement contains two one-year contract period renewals (1 + 1) to extend the contract for the periods 2028 and 2029. Estimated quantity for the contract period including contract period renewals is 112,000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest price. Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, annexes: Annex 1 Contract Annex 2 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 3 Delivery schedule Annex 4 Subcontractors Annex 5 Description of the Handi Service

Lisätiedot

The purpose of STM and the Customer is to procure Meningococcal group A, C, W-135 and Y conjugate vaccine required for the vaccinations in the Finnish Defence Forces and the Finnish Border Guard and for the risk group vaccinations in the National Vaccination Programme in Finland. The tendered vaccine must be suitable for adults and children according to Article´s Summary of Product Characteristics (SPC). The Customer should prefer syringes without fixed needles. This procurement is not divided into lots. According to Communicable Diseases Act (1227/2016) the Finnish Institute for Health and Welfare has an obligation to supervise the implementation of the national immunization programme and other general vaccinations and monitor the implementation and impact of the vaccinations. Implementing and supervising the implementation of the national immunization programme is practical with one suitable vaccine. In addition pursuant to Section 2 of the Act on Public Procurement and Concession Contracts (Procurement Act), the contracting entity seeks to enhance efficiency in the use of public funds and arrange their procurement operations so that procurements can be implemented with optimal economy, quality and orderliness, taking advantage of existing competitive conditions and allowing for environmental and social aspects. These fundamental aims will be achieved by procuring one suitable vaccine for all target groups. The target groups for the Meningococcal group A, C, W-135 and Y conjugate vaccine are the conscripts in the Finnish Defence Forces and the Finnish Border Guard and the medical risk groups in the National Vaccination Programme. More information about National Vaccination Programme and vaccinations can be found on the website of the Finnish Institute for Health and Welfare: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/meningokokkirokotteet/meningokokki-acwy-rokote The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Call for Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. If the Supplier has modified vaccine available/releases a modified vaccine during the contract period, the Parties may agree to substitute the Article with the modified vaccine. In case of substitution, all terms and prices in the Contract shall apply without modification. CONTRACT PERIOD The Contract shall enter into a force once the competent signatories of both the Contracting Parties have duly signed the Contract. The Contract shall expire when all contractual duties and obligations have been performed by both Parties. However, the contract period shall be counted from the first day of the month on which the Supplier has handed over the first delivery of the Articles to the Customer´s pharmaceutical wholesaler. The Contract period is two (2) years from the date defined previously above and the estimated quantity to be purchased for this period is 56,000 +/- 20% doses. After the contract period, the Customer reserves the right for the contract period renewals described in section "Description of renewals". Tenders will be compared in the manner described in section "Grounds for decision" of the Call for Tenders.

Hankinnan vaiheet

  1. Hankintailmoitus

    Tarjouspyyntö julkaistiin, määräaika 4.6.2025 klo 12.00.

  2. Jälki-ilmoitustämä ilmoitus

    Voittaja: GlaxoSmithKline Oy.

Lähde: Hilma (hankintailmoitukset.fi)

Ilmoitus 2025-030700

Ilmoita virheestä tai pyydä poistoa